I suppose a lot of hope is in China and other countries which don't follow FDA guidelines so may go with trials faster :)
Well, Dr Zlotnick is a world authority onHBV core protein capsid. He has not yet chosen a CpAM modifier for clinical studies. Novira is presently conducting a clinical trial (phase I) of its NVR3-778. China has one in clinical trial (phase 2b), but shrouded in mystery.